CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Non-Hodgkin Lymphoma Faculty

Michele E Ghielmini, MD, PhD
Honorary Professor of Medicine
University of Bern
Medical Director
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland

Advisory Committee: Celgene Corporation, GlaxoSmithKline; Consulting Agreement: Millennium: The Takeda Oncology Company; Speakers Bureau: Mundipharma International Limited, Pfizer Inc, Roche Laboratories
Inc.

Steven M Horwitz, MD
Assistant Attending
Lymphoma Service
Division of Hematologic Oncology
Memorial Sloan-Kettering Cancer Center
New York, New York

Consulting Agreements: Allos Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Genzyme Corporation, Janssen Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Kyowa Hakko Kirin Co Ltd, Millennium: The Takeda Oncology Company, Seattle Genetics; Contracted Research: Allos Therapeutics, Celgene Corporation, Infinity Pharmaceuticals Inc, Kyowa Hakko Kirin Co Ltd, Millennium: The Takeda Oncology Company, Seattle Genetics, Spectrum Pharmaceuticals Inc.

Brad S Kahl, MD
Skoronski Chair of Lymphoma Research
Associate Professor
University of Wisconsin School of Medicine and Public Health
Associate Director for Clinical Research
UW Carbone Cancer Center
Madison, Wisconsin

Advisory Committee: Celgene Corporation, Cephalon Inc, Genentech
BioOncology, Millennium: The Takeda Oncology Company, Roche
Laboratories Inc; Contracted Research: Abbott Laboratories, Cephalon Inc, Genentech BioOncology.

Laurie H Sehn, MD, MPH
Centre for Lymphoid Cancer
BC Cancer Agency and University of British Columbia
Vancouver, British Columbia, Canada

Consulting Agreements: Amgen Inc, Celgene Corporation, Cephalon Inc, Genentech BioOncology, Gilead Sciences Inc, GlaxoSmithKline, Lundbeck Canada Inc, Roche Laboratories Inc; Contracted Research: Lundbeck Canada Inc, Roche Laboratories Inc.

Mitchell R Smith, MD, PhD
Director of Lymphoid Malignancies Program at Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Advisory Committee: Celgene Corporation, Cephalon Inc; Speakers Bureau: Allos Therapeutics, Spectrum Pharmaceuticals Inc.

Multiple Myeloma Faculty

William I Bensinger, MD
Professor of Medicine, University of Washington
Member, Fred Hutchinson Cancer Research Center
Director, Autologous Stem Cell Transplant Program
Seattle, Washington

Advisory Committee: Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc, Sanofi; Consulting Agreement: Celgene Corporation; Contracted Research: Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation.

Meletios A Dimopoulos, MD
Chairman, Department of Medical Therapeutics
University of Athens School of Medicine
Athens, Greece

Advisory Committee: Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.

Amrita Krishnan, MD
Director, Multiple Myeloma Program
City of Hope Cancer Center
Duarte, California

Advisory Committee: Celgene Corporation, Onyx Pharmaceuticals Inc; Ownership Interest: Celgene Corporation; Speakers Bureau: Celgene Corporation, Genentech BioOncology, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center 
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Advisory Committee: Amgen Inc, Celgene Corporation; Consulting Agreements: Lilly, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Contracted Research: Acetylon Pharmaceuticals Inc, Amgen Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation.

A Keith Stewart, MBChB
Dean for Research, Mayo Clinic in Arizona
Consultant, Division of Hematology/Oncology
Vasek and Anna Maria Polak Professorship in Cancer Research
Scottsdale, Arizona

Advisory Committee: Amgen Inc, Celgene Corporation; Consulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company; Contracted Research: Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.

This material may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec, Lilly, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc and Teva Oncology.